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II. ABSTRAK 
Pengenalan  
Ujian tinja (najis) telah digunakan sebagai ujian saringan untuk mengenalpasti kanser 
kolorektal. Ujian ‘guaiac FOBT’ adalah terbatas disebabkan oleh kadar sensitiviti dan 
spesifisiti yang rendah. Kehadiran ‘tumour M2-PK’ di dalam tinja pesakit-pesakit yang 
menghidap kanser kolorektal dan ‘polyp’ kolorektal sedang diselidik sebagai potensi 
menjadikannya ujian saringan kanser kolorektal.      
 
Objektif  
Untuk mengkaji penggunaan ujian tinja ‘tumour M2-pyruvate kinase’ dalam 
mengenalpasti kanser kolorektal dan membandingkannya dengan ujian saringan tinja yang 
digunakan pada masa kini iaitu ujian ‘guaiac FOBT’. 
 
Kaedah  
 Pesakit-pesakit simptomatik yang dirujuk untuk pemeriksaan kolonoskopi elektif di 
HUSM memberikan sampel tinja untuk dianalisa berkenaan kehadiran ‘tumour M2-PK’ dan 
kehadiran darah di dalam tinja tersebut. Untuk ujian M2-PK, sampel tinja tersebut diperiksa 
menggunakan ujian komersial yang tersedia, ‘Schebo M2-PK Quick’. Untuk ujian ‘gFOBT’, 
sampel tinja yang sama dihantar ke makmal HUSM untuk dianalisa berkenaan kehadiran 
darah di dalamnya. Tiada perbatasan makanan dilakukan bagi kedua-dua ujian. Keputusan 
kedua-dua ujian dibandingkan dengan keputusan kolonoskopi (atau/dan dengan keputusan 
histopatologi). 
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Keputusan  
Seramai 85 subjek (purata umur ± sisihan piawai, 56.8 ± 15.3 tahun) direkrut. 17 
pesakit kanser kolorektal dan 10 pesakit ‘adenoma’ kolon dikesan. Sensitiviti ujian M2-PK 
terhadap pengesanan kanser kolorektal adalah lebih tinggi berbanding ujian gFOBT (100.0% 
vs 64.7%). Walau bagaimanapun, ujian M2-PK mempunyai spesifisiti yang lebih rendah 
apabila dibandingkan dengan ujian gFOBT (72.5% vs 88.2%). ‘Positive predictive value’ dan 
‘negative predictive value’ bagi ujian M2-PK masing-masing adalah  47.2% dan 100.0%, 
manakala bagi ujian gFOBT masing-masing adalah 57.9% and 90.9%. Kedua-dua ujian M2-
PK dan ujian gFOBT mempunyai sensitiviti yang rendah dalam mengenalpasti kehadiran 
‘adenoma’ kolon (20.0% vs 30.0%). Spesifisiti ujian M2-PK adalah 54.7%, iaitu lebih rendah 
berbanding ujian gFOBT yang mempunyai spesifisiti 78.7%. 
 
Kesimpulan  
Ujian M2-PK Quick mempunyai sensitiviti yang sangat tinggi sebagai penanda tinja 
bagi pengesanan kanser kolorektal apabila dibandingkan dengan ujian gFOBT. Ianya cepat 
dan mudah dilakukan di peringkat klinikal, maka ianya sesuai dijadikan sebagai ujian awal 
saringan untuk kanser kolorektal. Bagi mereka yang mempunyai ujian positif, mereka perlu 
menjalani ujian penilaian yang seterusnya. Walau bagaimanapun, peranannya dalam 
pengesanan ‘adenoma’ kolorektal adalah sangat terbatas.  
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III. ABSTRACT   
Introduction  
Stool tests have been used in colorectal cancer screening. Guaiac FOBT is limited by 
its low sensitivity and specificity. The determination of tumour M2-PK in stool of patients 
with colorectal cancer and colorectal polyp has been investigated as a potential stool test for 
colorectal cancer screening. 
 
Objectives  
 To evaluate the use of faecal tumour M2-pyruvate kinase test in detection of 
colorectal cancer and to compare it with the current surveillance tool, guaiac faecal occult 
blood test. 
 
Methodology  
 Symptomatic subjects who were referred for elective colonoscopy in HUSM provided 
stool samples for analysis of tumour M2-PK and occult blood. For M2-PK test, the stool 
sample was tested using a commercially available rapid test, ScheBo M2-PK Quick. For 
gFOBT, the stool sample was sent to HUSM’s laboratory following usual practice to detect 
faecal hemoglobin. No dietary restrictions were applied for both tests. The results of both 
tests were compared with colonoscopic result (and/ or with histopathology report).   
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Results  
85 subjects (mean age ± SD, 56.8 ± 15.3 years) were enrolled. A total of 17 (20.0%) 
colorectal cancer and 10 (11.8%) colorectal adenoma were detected. The sensitivity of M2-
PK test towards detection of colorectal cancer was higher than gFOBT (100.0% vs 64.7%). 
However, M2-PK test had a lower specificity when compared with gFOBT (72.5% vs 
88.2%). The positive predictive value and negative predictive value of faecal M2-PK test 
were 47.2% and 100.0% respectively, whereas for guaiac FOBT were 57.9% and 90.9% 
respectively. Both M2-PK test and gFOBT had low sensitivity towards detection of colorectal 
adenoma (20.0% vs 30.0%). The specificity of M2-PK test was 54.7%, which was lower than 
gFOBT which had higher specificity of 78.7%. 
 
Conclusion  
Faecal M2-PK Quick test has a high sensitivity for detection of colorectal cancer as a 
stool biomarker when compared with gFOBT. It is fast and easy to be performed in clinical 
settings, thus suitable for initial screening tool for colorectal cancer. Those with positive 
result should undergo further complete diagnostic evaluation. However, its role for detection 
of colorectal adenoma is very limited.   
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1 – INTRODUCTION  
1.1 LITERATURE REVIEW 
 
M2 Pyruvate Kinase and Cancer Metabolism 
In contrast to normal proliferating cells, tumour cells consume more glucose and 
generate high amounts of lactate to produce energy. Tumour cells exhibit a high rate of 
glycolysis in generating adenosine triphosphate (ATP), rather than using oxidative 
phosphorylation, even when abundant of oxygen is presence. This phenomenon is known as 
aerobic glycolysis or Warburg effect, which provides energy and metabolic intermediates to 
the tumour cells for the synthesis of amino acids, nucleic acids, lipids and other 
macromolecules to facilitate growth and survival of tumour cell. Cancer cells are shown to 
express pyruvate kinase type M2, and play a crucial role in the Warburg effect (Yang et al., 
2014). 
Pyruvate kinase is an enzyme that catalyzes the final step of glycolysis by conversion 
of phosphoenolpyruvate and adenosine diphosphate (ADP) to pyruvate and ATP, and 
production of lactate. Unlike mitochondrial respiration, production of energy by pyruvate 
kinase is independent of oxygen and allows survival of cells under condition of insufficient 
oxygen, which is an important metabolic ability in tumour cells
 
(Mazurek, 2008).  
Tumour cells have to survive in unfavorable atmospheres with lack of oxygen and 
nutrient. The expression of M2- pyruvate kinase (M2-PK) allow anaerobic metabolism to 
maintain metabolic activities and ATP production in the deficient-oxygen environment, 
allowing the tumour cells to proliferate, grow and survive. High lactate production by aerobic 
glycolysis has been found to increase metastasis of tumour cells and angiogenesis by 
stimulating cytokines, such as vascular endothelial growth factor (VEGF) and interleukin-8 
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(IL-8). Tumour cells also produce bicarbonic and lactic acids, which favor acidic 
environment that enhance tumour metastasis (Zhou et al., 2012). 
The Isoforms of Pyruvate Kinase 
There are 4 types of pyruvate kinase isoforms (L, R, M1 and M2) that are expressed 
in different cells and tissues depend on its metabolic activities. Pyruvate kinase type L is 
responsible in gluconeogenesis and thus, found in liver and kidney. Pyruvate kinase type R is 
dominant in erythrocytes. M1 isoenzyme is present in tissues that require large amounts of 
ATP such as in skeletal muscle and brain, whereas M2 is mainly expressed in lung tissues 
and cells with high rates of nucleogenesis such as adult stem cells, embryonic cells and 
especially tumour cells (Mazurek et al., 2005). 
M2-PK exists in 2 oligomeric forms. The tetrameric form of M2-PK is present in lung 
and normal proliferating cells, while dimeric form is predominate in tumour cells, and have 
been termed tumour M2-PK (Hardt and Ewald, 2008; Mazurek et al., 2005).   
Proliferating cells express pyruvate kinase type M2 and is progressively replaced by 
other isoforms during tissue differentiation. However, during tumourigenesis the tissue 
specific isoenzymes, such as L-PK in liver, disappear and M2-PK is expressed (Iqbal et al., 
2014).   
 
Tumour M2-PK: a Tool for Early Detection of Tumour 
Tumour M2-PK is released by tumour cells into the blood and also into the stool of 
patients with gastrointestinal tumour, most probably due to tumour necrosis and cell turnover, 
providing the opportunity of diagnostic approaches (Mazurek, 2008). Higher amount of 
tumour M2-PK is detected in the EDTA plasma of patients with renal cell carcinoma, 
melanoma, esophageal, lung, pancreatic, cervical, ovarian, breast, gastric, and colorectal 
cancer. The presence of tumour M2-PK also has been detected in stool of patients with 
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colorectal and gastric cancer, and correlate with colorectal cancer stages (Mazurek, 2008).  
The presence of M2-PK in plasma and stool has been used to monitor failure, success or 
recurrence of disease during therapy (Mazurek, 2012).  
Tumour M2-PK can be measured and quantified in blood by using enzyme-linked 
immunosorbent assay (ELISA) technique. The test is based on 2 monoclonal antibodies that 
react specifically with tumour M2-PK and do not cross-react with other pyruvate kinase 
isoenzymes (type R, L and M1). A reference value of 15U/ml in EDTA plasma correspond to 
a sensitivity of 57.3%,  specificity of 89%, positive predictive value of 85.7% and  negative 
predictive value of 64.8% for colorectal cancers. For gastric/ esophageal cancers, the 
sensitivity was 62.1%, specificity was 89%, positive predictive value was 88% and negative 
predictive value was 64%, whereas for pancreatic cancers, , the sensitivity was 72.5%, 
specificity was 89%, positive predictive value was 58% and negative predictive value was 
94% (Kumar et al., 2007). 
Tumour M2-PK can be detected in faeces by a similar ELISA technique used in 
plasma assay. A reference value of 4 U/ml corresponds to a sensitivity of 73-92% and 
specificity of 83% (Kumar et al., 2007). 
 
M2-PK in Stool: a Marker for Colorectal Cancer Screening 
M2-PK is overexpressed in colon cancer cells compared to normal cells. 
Overexpression of M2-PK is associated with later tumour stage and more lymph node 
metastasis in colorectal cancer patients, indicating that M2-PK is involved in tumour growth 
and metastasis. M2-PK is also found in healthy colon but at a lower level, suggesting that 
M2-PK is unspecific to cancer cells (Zhou et al., 2012). 
Tumour M2-PK can be measured in faeces of GI malignancy patients, mainly in 
colorectal cancer by using enzyme-linked immunosorbent assay (ELISA) technique, 
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favouring a possible colorectal cancer tumour marker. Furthermore, the M2-PK test can 
detect bleeding or non-bleeding GI cancer and polyps (Tonus et al., 2012).  
There are several studies concerning the use of tumour M2-PK in colorectal cancer 
screening. 
Hardt et al conducted a study on 206 patients to determine the use of faecal tumour 
M2-PK as a screening tool for colorectal tumours. They revealed a significantly higher level 
of faecal tumour M2-PK in patients with colorectal cancer than in the control group without 
colorectal cancer. Overall sensitivity is 73% and specificity is 78%. There was a strong 
correlation between the levels of faecal tumour M2-PK and staging. The sensitivities 
increased from 57% and 59% in the case of T1 and Dukes’ A, respectively, to 78% in the 
case of T4 and 90% in the case of Dukes’ D (Hardt et al., 2004).  
Abdullah et al recruited 328 patients with high-risk and symptomatic group to 
evaluate the performance of faecal tumour M2-PK as a diagnostic biomarker for colorectal 
cancer screening. The sensitivity and specificity of the faecal tumour M2-PK test towards 
colorectal cancer were 71.4% and 71.0% respectively. However, it has a low sensitivity for 
detecting adenomas (Abdullah et al., 2012).  
In a different study, Haug et al performed a comparative analysis to estimate the 
potential of faecal tumour M2-PK in discriminating patients with colorectal cancer from 
unselected older adults aged 50-75 years. The study recruited 65 colorectal cancer patient and 
917 unselected older adults. The results showed sensitivity of 85% for colon cancer and 56% 
for rectal cancer. The specificity for detecting colorectal cancer was estimated to be 79% 
(Haug et al., 2007). 
Koss et al recruited 55 patients to assess faecal tumour M2-PK levels along the 
adenoma-carcinoma sequence and to evaluate its levels in different colorectal cancer stages. 
The study reported sensitivity of 20% for polyps smaller than 10mm and 60% for polyps 
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greater than 10mm with specificity of 92%. The sensitivity for colorectal cancer was 91% 
and specificity was 92%. There was no association found between tumour size and faecal 
tumour M2-PK level.  The faecal tumour M2-PK level was noted to be higher in patients with 
colorectal cancer stages Duke’s B and C than Duke’s A.  The study also observed significant 
reduction in faecal tumour M2-PK levels at 6 months following successful surgical 
intervention (Koss et al., 2007).  
Haug et al recruited 1082 average-risk subjects aged 55 years or older for screening 
colonoscopy to investigate the potential of the faecal tumour M2-PK to detect colorectal 
adenoma. The study reported a low sensitivity of 22% for advanced adenoma and 23% for 
other adenoma, whereas specificity was 82%. They concluded that the tumour M2-PK has a 
very limited role in detection of colorectal adenoma (Haug et al., 2008).  
A similar result reported by Ewald et al, they found that the overall sensitivity of 
adenoma was 45.9%, increasing to 61.1% for adenomas larger than 1 cm (Ewald et al., 
2007).    
A meta-analysis performed by Tonus et al reported a relatively good performance of 
faecal tumour M2-PK in colorectal cancer screening with a mean sensitivity and specificity 
of 80.3% and 95.2% respectively.  For adenoma, the sensitivity were 25% for adenoma <1cm 
in diameter, 44% for adenoma >1cm and 51% for adenoma of unspecified diameter. The 
author recommended the faecal tumour M2-PK as a routine test for colorectal cancer 
screening as faecal M2-PK is able to detect bleeding and non-bleeding tumours and adenoma 
with high sensitivity and specificity (Tonus et al., 2012).  
Recently, Sithambaram et al performed a validation study on the use of a rapid, point 
of care stool test M2-PK for the detection of colorectal cancer. The faecal M2-PK was tested 
in 100 colorectal cancer patients and 200 subjects with normal colonoscopy. The 
performance of M2-PK Quick revealed sensitivity of 93%, specificity of 97.5% and 
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diagnostic accuracy of 96%. The test was found to be highly accurate regardless of the 
tumour stages and location (Sithambaram et al., 2015).  
 
1.2 RATIONALE FOR THE STUDY 
A highly sensitive and specific yet non-invasive and acceptable screening tool for colorectal 
cancer is of major importance for lowering the incidence of colorectal cancer. The aim of this 
study is to evaluate the potential use of faecal tumour M2-PK to detect colorectal cancer and 
compare it with the current surveillance tool, guaiac FOBT. 
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A. Project Identification 
Title of Study:  
The Use of Tumour M2 Pyruvate Kinase as a Stool Biomarker for Detection of 
Colorectal Cancer in Hospital Universiti Sains Malaysia. 
 
B. Introduction  
According to World Health Organisation’s GLOBOCAN 2012, estimated about 
37,400 persons were diagnosed with new cancer in Malaysia and colorectal cancer (CRC) is 
the second most common cancer in men (14.1%) and the third in women (10.2%)
1
. 
Approximately, 10.6% patients died due to CRC that year, which makes it the third most 
common death from cancer (after lung cancer with approximately 19.1% death and breast 
cancer 11.9% in 2012)
1
. The cumulative lifetime risk of developing colon cancer in males 
was 1:38 and 1:50 for females
2
. The incidence and mortality of CRC is rising rapidly in 
Asia
3
, with majority of patients are above 50 years old
4
. Many Asian countries, including 
China, Japan, South Korea, and Singapore, have an increase of two to four times in the 
incidence of CRC during the past few decades
5
, despite availability of screening methods.  
Most CRC can be prevented by detection of early-stage adenocarcinoma, and 
detection and removal of adenomatous polyps, and survival is significantly better when CRC 
is diagnosed while still localized
6
. Incidence and mortality due to CRC can be effectively 
reduced with early diagnosis, if regular screening is done
6
. However, a study by Harmy et al, 
2012 showed that participation in CRC screening among average risk in Malaysia is 
extremely low mainly due to embarrassment, uncomfortable and some patients mentioned 
never being advised to do screening
7
.  
Current gold standard screening tool for early detection of CRC is colonoscopy, 
which has the most sensitivity and specificity. It allows direct mucosal inspection of the 
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entire colon and provides the opportunity to perform an excision for an adenoma and to take a 
histological sample from a suspected neoplasia
6
. However, most patients refuse to participate 
because of its invasiveness. Non-invasive faecal test are much more acceptable as they are 
less invasive and less uncomfortable
7,8
. Currently available stool tests for CRC screening are 
faecal occult blood test (FOBT), genetic stool test and M2-pyruvate kinase (M2-PK) stool 
test. The most widely used is FOBT
9
.  According to Malaysian clinical practice guidelines on 
CRC screening 2001, the best approach to screen for CRC is by using FOBT as an annual 
screening to those at average risk. However, FOBT is limited by its low sensitivity towards 
colorectal polyps and frequent false-positive results
10
. Stool DNA test is not recommended by 
the Asia Pacific Consensus on CRC as this test is still in experimental phase and is not ready 
to be used as a routine screening test
11
. 
Pyruvate kinase is an enzyme that involved in glycolysis by catalysing the ATP 
regenerating dephosphorylation of phosphoenolpyruvate to pyruvate
12
. Type M2-PK is a 
special isoenzyme of pyruvate kinase which is expressed by proliferating cells
12,13
. The 
dimeric form, termed tumour M2-PK is predominantly overexpressed in tumour cells
12,14,15
. 
M2-PK is essential in tumour growth of CRC by regulating cell proliferation and migration of 
colon cancer cells
13
. Greater amount of this isomer is found at later tumour stage
13,16
 and 
associated with lymph metastasis in CRC patients
13
. Tumour M2-PK has also been found in 
the stool of patients with CRC
9
 and colorectal polyps
12
. The amount of M2-PK in stool can 
be quantified by ELISA
12
 and thus faecal M2PK has been proposed as a tool for detecting 
CRC
17,18,19
. 
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C. Justification  
A highly sensitive and specific yet non-invasive and acceptable screening tool for 
CRC is of major importance for lowering the incidence of CRC. This study is aimed to 
evaluate the potential of the faecal tumour M2-PK test to detect CRC and compare it with 
guaiac-based FOBT. 
 
D. Objectives of Study 
General objective 
- To evaluate the use of faecal M2-pyruvate kinase test in detection of colorectal 
cancer. 
 
Specific objectives 
- To determine the sensitivity specificity, positive predictive value and negative 
predictive value of faecal M2-pyruvate kinase test towards detection of colorectal 
cancer.  
- To compare the diagnostic accuracy of faecal M2-pyruvate kinase with current 
surveillance tool, faecal occult blood test (FOBT) in detecting colorectal cancer.  
 
E. Research Question 
Is faecal M2-PK test is a more accurate test compare to guaiac-based FOBT for the 
detection of colorectal cancer? 
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F. Hypothesis  
Faecal M2-PK test has high sensitivity and specificity in detecting colorectal cancer. 
Faecal occult blood test has low sensitivity and specificity in detecting colorectal 
cancer. 
 
G. Null Hypothesis  
Faecal M2-PK test has lower sensitivity and specificity compare to guaiac-based 
FOBT in detecting colorectal cancer. 
 
H. Research Methodology 
Study design 
This is a cross-sectional study which would be carried out in Hospital Universiti Sains 
Malaysia after the approval by the university Ethics Committee.  
 
Study population  
All adult patients who referred for elective colonoscopy for various indication at Hospital 
Universiti Sains Malaysia.  
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Patient selection   
- The subjects of the study will be consented, explained the aim and the risks of the 
study. 
- Adult patients undergoing colonoscopy for various indications like CRC screening, 
investigation of colonic symptoms, high risk for CRC, family history of CR neoplasia, 
and clinical suspicion of CRC will be considered for enrolment into the study. 
- Exclusion criteria consist of the following: patient who presents as emergency cases 
(eg: obstruction), past history of colectomy, patient known to have CRC and came for 
surveillance colonoscopy, underwent chemotherapy for CRC.  
 
Patients’ recruitment 
Patients attending and/or referred to surgical out-patient clinics at Hospital Universiti Sains 
Malaysia and planned for elective colonoscopy.  
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Sample size calculations 
From the literature review, a study by Hajhamad et al reported the sensitivity of a 
positive faecal tumour M2-PK test for colorectal cancer are 100%
30
. Sithambaram et al, 
reported a specificity of 97.5%
29
. Based on this, sample size calculated:  
 
Sample size (n) based on sensitivity  n = Zα/2
2
 SN (1-SN)          SN = Sensitivity 
L
2 
P           L = Absolute  
precision 
                  P = Prevalence 
   SP = Specificity 
Sample size (n) based on specificity  n = Zα/2
2
 SP (1-SP)           
       L
2
 (1-P)   
 
Alpha  =  5%  n for sensitivity  = 84.7 
Zα/2
 
  = 1.95    n for specificity  = 8.7 
  
Precision =  5% 
Prevalence  = 13%    Final sample size = 84.7 
Sensitivity  = 100%    Anticipate dropout  = 10% 
Specificity  = 98%    Final sample size = 95 
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Measurement Tool 
- Patients’ demographic will be collected using standard data form.  
- The subjects who have consented to participate in the study will be given a clean 
plastic container and a plastic spoon for stool sample collection. 
- They have to collect 2 stool samples before bowel preparation for colonoscopy as they 
present for scope day.  
- The stool received will be analysed within 2 days after sampling, as recommended by 
the manufacturer.  
- For FOBT, the stool sample will be sent to laboratory following usual practice to 
detect haemoglobin in the faeces.  
- For M2-PK test, random stool sample will be collected according to the 
manufacturer’s instructions and the faecal tumour M2-PK will be detected using a 
commercially available rapid test, ScheBo M2-PK Quick (ScheBo® Biotech AG, 
Giessen, Germany) based on monoclonal antibodies against dimeric M2-PK.  
- Another stool sample will be send to HUSM’s laboratory for faecal occult blood 
testing.  
- No dietary restrictions are required prior to stool collections.  
- Colonoscopy will be performed by experienced endoscopists according to the current 
practice at Endoscopy Unit, HUSM, with visualization of the entire colon up to 
caecum using a standard colonoscope after routine bowel preparation. 
- Patients with incomplete colonoscopies will be proceed with CT colonography or 
barium enema or repeat colonoscopy to complete colonic examination. 
- After colonoscopy is performed, reports on colonoscopy will be collected and 
information will be extracted in a standardised manner. 
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- Any found lesions during colonoscopy (or repeat colonoscopy) will be biopsied and 
the tissue biopsy will be studied by Pathology Department at HUSM according to 
current practice and histological reports will be collected and information will be 
extracted in a standardised manner. 
- The results of M2-PK test and FOBT will be labelled as positive or negative and both 
will be analysed and compared to the colonoscopic findings with or without 
histopathology examination. 
 
Statistical analysis 
Data will be analysed using Statistical Package for the Social Sciences (SPSS) version 
22. Descriptive analysis will be done for patients’ demographic on age, gender and ethnicity 
to give an overall picture of epidemiology trend of this study. Cross tabulation will be done to 
determine the true positive, true negative, false positive and false negative results to calculate 
the sensitivity and specificity values of faecal M2-PK test. Calculation of sensitivity and 
specificity values are as below: 
Sensitivity = TP / (TP + FN) 
 TP = true positive data, FN = false negative data 
Specificity = TN / (TN + FP)  
 TN = true negative data, FP = false positive data 
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Figure 1: Methodology Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identifying patients for inclusion into study 
-patients attend for out-patient clinic and planned for elective colonoscopy 
Fulfilled on Inclusion criteria 
Patients are required to collect stool samples at 
home before bowel preparation for colonoscopy  
Fulfilled on Exclusion criteria 
Excluding  
Yes, Including   
Positive findings  biopsy 
Stool sample analysis at scope room, and the 
results are blinded to endoscopist 
Data collection on colonoscopy and histological 
findings, tumour M2-PK test and gFOBT results 
Result 
Data analysis 
Patients undergo colonoscopy Normal colonoscopy 
CT colonography/ barium enema/ repeat 
colonoscopy 
Incomplete colonoscopy 
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I. Expected Results 
Table 1 – Patients’ Demographics 
Patients’ demographics No. (%) 
Frequency   
 Age (years)    
Gender  
   Male  
   Female 
  
Ethnicity  
   Malay  
   Chinese 
   Indian  
   Others 
  
 
Table 2 – Result of faecal M2PK test in relation to colonoscopy findings 
Colonoscopy findings Total M2PK test positive M2PK test negative  
No. No. (%) No. (%) 
Colorectal cancer       
Colorectal adenoma      
Normal or non-neoplastic lesion      
 
Table 3 – Result of FOBT test in relation to colonoscopy findings 
Colonoscopy findings Total FOBT positive FOBT negative  
No. No. (%) No. (%) 
Colorectal cancer       
Colorectal adenoma      
Normal or non-neoplastic lesion      
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Table 4 – Performance characteristics of faecal tumour M2PK and FOBT in different 
diagnostic groups 
Parameter Tumour M2PK gFOBT 
Sensitivity (%) 
  Colorectal cancer 
  Colorectal adenoma 
  
Specificity (%) 
  Colorectal cancer 
  Colorectal adenoma 
  
Positive predictive value (%) 
  Colorectal cancer 
  Colorectal adenoma 
  
Negative predictive value (%) 
  Colorectal cancer 
  Colorectal adenoma 
  
Positive likelihood ratio (%) 
  Colorectal cancer 
  Colorectal adenoma 
  
Negative likelihood ratio (%) 
  Colorectal cancer 
  Colorectal adenoma 
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J. Sample Data Collection Form 
PROFORMA 
A prospective study of faecal M2-PK in detecting CRC in HUSM 
Study ID:          Age:  
Gender: male (   ), female (   )                 Race: Malay (   ), Chinese (   ), India (   ), Others (   ) 
 
Indications for colonoscopy:  
 (   ) gastrointestinal bleeding 
(   ) abdominal pain 
 (   ) change in bowel habits 
 (   ) CRC screening  
 (   ) abdominal mass 
 
Faecal M2-PK test: positive (   ), negative (   )                    gFOBT: positive (   ), negative (   ) 
 
Colonoscopy results: (complete/ incomplete) 
carcinoma (   ), adenoma (   ), colitis (   ), others pathology (   ), normal (   ) 
 
CT colonography/ Barium enema/ Repeat colonoscopy result:  
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K. Gantt Chart  
Month J J A S O N D J F M A M J J A S O N D J F M A M 
Year 2014 2015 2016 
Data collection X X X X X X X X X X X X             
Data analysis        X X X X X X X           
Report writing              X X X X X X       
Submission of paper                   X X X    
Publication of research                        X X X 
 
Milestones of Research Activities: 
1. Completion of data collection   :  May 2015 
2. Completion of data analysis   :  July 2015  
3. Completion of report writing   :  November 2015 
4. Completion of paper submission   : February 2016 
5. Completion of research publication   : May 2016 
